92 related articles for article (PubMed ID: 21352561)
1. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial.
Witzens-Harig M; Hensel M; Unterhalt M; Herfarth K
BMC Cancer; 2011 Feb; 11():87. PubMed ID: 21352561
[TBL] [Abstract][Full Text] [Related]
2. Follicular lymphoma in the United States: first report of the national LymphoCare study.
Friedberg JW; Taylor MD; Cerhan JR; Flowers CR; Dillon H; Farber CM; Rogers ES; Hainsworth JD; Wong EK; Vose JM; Zelenetz AD; Link BK
J Clin Oncol; 2009 Mar; 27(8):1202-8. PubMed ID: 19204203
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.
Tobin JWD; Rule G; Colvin K; Calvente L; Hodgson D; Bell S; Dunduru C; Gallo J; Tsang ES; Tan X; Wong J; Pearce J; Campbell R; Tneh S; Shorten S; Ng M; Cochrane T; Tam CS; Abro E; Hawkes E; Hodges G; Kansara R; Talaulikar D; Gilbertson M; Johnston AM; Savage KJ; Villa D; Morris K; Ratnasingam S; Janowski W; Kridel R; Cheah CY; MacManus M; Matigian N; Mollee P; Gandhi MK; Hapgood G
Blood Adv; 2019 Oct; 3(19):2804-2811. PubMed ID: 31570492
[TBL] [Abstract][Full Text] [Related]
4. Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma.
Rutherford SC; Yin J; Pederson LD; Blum KA; Martin P; Jung SH; Grant B; Rosenbaum C; Cheson BD; Bartlett NL; Mandrekar SJ; Leonard JP
Blood Adv; 2024 Mar; 8(6):1464-1468. PubMed ID: 38266151
[No Abstract] [Full Text] [Related]
5. Initial management strategies for follicular lymphoma.
Chen Q; Ayer T; Nastoupil LJ; Seward M; Zhang H; Sinha R; Flowers CR
Int J Hematol Oncol; 2012 Oct; 1(1):35-45. PubMed ID: 23476737
[TBL] [Abstract][Full Text] [Related]
6. Grade 3A follicular lymphoma can be effectively controlled with very low-dose radiation therapy.
Imber BS; Chau K; Goldberg E; Joffe E; Yahalom J
Leuk Lymphoma; 2020 Jun; 61(6):1500-1503. PubMed ID: 32037915
[No Abstract] [Full Text] [Related]
7. Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal?
Mondello P; Steiner N; Wasle I; Pitini V; Mian M
Anticancer Res; 2014 Nov; 34(11):6701-4. PubMed ID: 25368277
[TBL] [Abstract][Full Text] [Related]
8. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.
Kahl BS; Hong F; Williams ME; Gascoyne RD; Wagner LI; Krauss JC; Habermann TM; Swinnen LJ; Schuster SJ; Peterson CG; Sborov MD; Martin SE; Weiss M; Ehmann WC; Horning SJ
J Clin Oncol; 2014 Oct; 32(28):3096-102. PubMed ID: 25154829
[TBL] [Abstract][Full Text] [Related]
9. Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database.
Abou-Nassar KE; Vanderplas A; Friedberg JW; Abel GA; Niland J; Rodriguez MA; Czuczman MS; Millenson M; Crosby A; Gordon LI; Zelenetz AD; Kaminski M; Lacasce AS
Leuk Lymphoma; 2013 Oct; 54(10):2155-62. PubMed ID: 23343180
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Leuk Lymphoma; 2015; 56(8):2350-6. PubMed ID: 25426666
[TBL] [Abstract][Full Text] [Related]
11. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
12. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
Federico M; Luminari S; Dondi A; Tucci A; Vitolo U; Rigacci L; Di Raimondo F; Carella AM; Pulsoni A; Merli F; Arcaini L; Angrilli F; Stelitano C; Gaidano G; Dell'olio M; Marcheselli L; Franco V; Galimberti S; Sacchi S; Brugiatelli M
J Clin Oncol; 2013 Apr; 31(12):1506-13. PubMed ID: 23530110
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.
Friedberg JW; Byrtek M; Link BK; Flowers C; Taylor M; Hainsworth J; Cerhan JR; Zelenetz AD; Hirata J; Miller TP
J Clin Oncol; 2012 Sep; 30(27):3368-75. PubMed ID: 22915662
[TBL] [Abstract][Full Text] [Related]
14. Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03.
MacManus M; Fisher R; Roos D; O'Brien P; Macann A; Davis S; Tsang R; Christie D; McClure B; Joseph D; Jayamohan J; Seymour JF
J Clin Oncol; 2018 Oct; 36(29):2918-2925. PubMed ID: 29975623
[TBL] [Abstract][Full Text] [Related]
15. Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial.
König L; Dreyling M; Dürig J; Engelhard M; Hohloch K; Viardot A; Witzens-Harig M; Kieser M; Klapper W; Pott C; Herfarth K
Trials; 2019 Aug; 20(1):544. PubMed ID: 31470902
[TBL] [Abstract][Full Text] [Related]
16. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University.
Mac Manus MP; Hoppe RT
J Clin Oncol; 1996 Apr; 14(4):1282-90. PubMed ID: 8648385
[TBL] [Abstract][Full Text] [Related]
17. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study.
Herfarth K; Borchmann P; Schnaidt S; Hohloch K; Budach V; Engelhard M; Viardot A; Engenhart-Cabillic R; Keller U; Reinartz G; Eich HT; Witzens-Harig M; Hess CF; Dörken B; Dürig J; Wiegel T; Hiddemann W; Hoster E; Pott C; Dreyling M
Hemasphere; 2018 Dec; 2(6):e160. PubMed ID: 31723798
[TBL] [Abstract][Full Text] [Related]
18. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV.
Los-de Vries GT; Stevens WBC; van Dijk E; Langois-Jacques C; Clear AJ; Stathi P; Roemer MGM; Mendeville M; Hijmering NJ; Sander B; Rosenwald A; Calaminici M; Hoster E; Hiddemann W; Gaulard P; Salles G; Horn H; Klapper W; Xerri L; Burton C; Tooze RM; Smith AG; Buske C; Scott DW; Natkunam Y; Advani R; Sehn LH; Raemaekers J; Gribben J; Kimby E; Kersten MJ; Maucort-Boulch D; Ylstra B; de Jong D
Blood Adv; 2022 Sep; 6(18):5482-5493. PubMed ID: 35816682
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin's lymphoma: a monocenter analysis.
Hadi I; Schummer A; Dreyling M; Eze C; Bodensohn R; Roengvoraphoj O; Belka C; Li M
Sci Rep; 2021 Nov; 11(1):22586. PubMed ID: 34799601
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
